Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.44 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 3/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.31 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17338963 | 0.82 | PIK3CA (0.43) | TGFBR1MAP3K14PIK3CAMTORFLT3 | |
| SCHEMBL25526880 | 0.79 | CYP1A2 (0.49) | TGFBR1MAP3K14TSHRGAAALDH1A1 | |
| SCHEMBL18766664 | 0.76 | IDO1 (0.47) | MAP3K14PIK3CAMTORFLT3GAA | |
| SCHEMBL18766613 | 0.76 | TGFBR1 (0.40) | TGFBR1MAP3K14PIK3CAMTORFLT3 | |
| SCHEMBL381224 | 0.76 | MAP3K14 (0.46) | MAP3K14PIK3CAMTORFLT3TSHR | |
| SCHEMBL18041661 | 0.76 | PIK3CA (0.47) | TGFBR1MAP3K14PIK3CAMTORFLT3 | |
| SCHEMBL3029604 | 0.75 | MAP3K14 (0.49) | MAP3K14PIK3CAMTORFLT3TSHR | |
| SCHEMBL31319787 | 0.73 | MAP3K14 (0.37) | TGFBR1MAP3K14PIK3CAMTORFLT3 | |
| SCHEMBL18766642 | 0.73 | PIK3CA (0.40) | TGFBR1MAP3K14PIK3CAMTORFLT3 | |
| SCHEMBL18766678 | 0.72 | HRH3 (0.39) | MAP3K14PIK3CAMTORAHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RELAY THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2025-04-24 | — | — | US | disclosed |
| US-12219327-B2 | Substituted isoindolines as PI3K-alpha inhibitors | RELAY THERAPEUTICS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| US-20240287058-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4415818-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| EP-4294798-A1 | FACTOR XIIA INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2023-12-27 | — | — | EP | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-116261562-A | PI 3K-alpha inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
| WO-2023064361-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-4143196-A1 | PI3K-a INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022175675-A1 | FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-08-25 | — | — | WO | disclosed |
| WO-2021222556-A1 | PI3K-α INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222556-A1 | PI3K-α INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | TGFBR1 1189/4885MAP3K14 3375/4885PIK3CA 1908/4885 |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | TGFBR1 3764/4885MAP3K14 137/4885PIK3CA 401/4885 |
| US-12219327-B2 | Substituted isoindolines as PI3K-alpha inhibitors | PIK3CD, PIK3CB, PIK3R1 | TGFBR1 2120/4885MAP3K14 302/4885PIK3CA 6/4885 |
| US-20240287058-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | TGFBR1 1867/4885MAP3K14 286/4885PIK3CA 1/4885 |
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | TGFBR1 3764/4885MAP3K14 137/4885PIK3CA 401/4885 |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RORB, ROR1, RORA | TGFBR1 155/4885MAP3K14 2438/4885PIK3CA 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.